JP6399920B2 - 体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤 - Google Patents
体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤 Download PDFInfo
- Publication number
- JP6399920B2 JP6399920B2 JP2014257747A JP2014257747A JP6399920B2 JP 6399920 B2 JP6399920 B2 JP 6399920B2 JP 2014257747 A JP2014257747 A JP 2014257747A JP 2014257747 A JP2014257747 A JP 2014257747A JP 6399920 B2 JP6399920 B2 JP 6399920B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- fucoxanthin
- lactoferrin
- composition
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000007935 neutral effect Effects 0.000 title claims description 34
- 210000000577 adipose tissue Anatomy 0.000 title claims description 33
- 235000021588 free fatty acids Nutrition 0.000 title claims description 24
- 230000004580 weight loss Effects 0.000 title claims description 19
- 239000003638 chemical reducing agent Substances 0.000 title claims description 16
- 210000004369 blood Anatomy 0.000 title claims description 15
- 239000008280 blood Substances 0.000 title claims description 15
- 239000003795 chemical substances by application Substances 0.000 title claims description 10
- 230000001737 promoting effect Effects 0.000 title claims description 6
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims description 73
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 67
- 108010063045 Lactoferrin Proteins 0.000 claims description 56
- 102000010445 Lactoferrin Human genes 0.000 claims description 56
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 56
- 229940078795 lactoferrin Drugs 0.000 claims description 56
- 235000021242 lactoferrin Nutrition 0.000 claims description 56
- 235000013305 food Nutrition 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 10
- 230000001603 reducing effect Effects 0.000 claims description 8
- NZEPSBGUXWWWSI-FWFPOGQTSA-N (3e,5e,7e,9e,11e,13e,15e)-18-[(2r,4s)-2,4-dihydroxy-2,6,6-trimethylcyclohexylidene]-1-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15,17-octaen-2-one Chemical compound C([C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)C(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O NZEPSBGUXWWWSI-FWFPOGQTSA-N 0.000 claims description 7
- LBCWAKKSVZUJKE-YGQWAKCJSA-N fucoxanthinol Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)CC12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=C=C3C(O)CC(O)CC3(C)C LBCWAKKSVZUJKE-YGQWAKCJSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 8
- 241000208202 Linaceae Species 0.000 claims 4
- 235000004431 Linum usitatissimum Nutrition 0.000 claims 4
- 229940075420 xanthine Drugs 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 239000003925 fat Substances 0.000 description 47
- 238000000034 method Methods 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 230000009467 reduction Effects 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000001596 intra-abdominal fat Anatomy 0.000 description 12
- 239000002207 metabolite Substances 0.000 description 11
- 210000004003 subcutaneous fat Anatomy 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- -1 iron ion Chemical class 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940002508 ginger extract Drugs 0.000 description 4
- 235000020708 ginger extract Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 3
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940072440 bovine lactoferrin Drugs 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000584629 Aosa Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000206608 Pyropia tenera Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010038047 apolactoferrin Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940019778 diethylene glycol diethyl ether Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
[1]成分(a):ラクトフェリンと成分(b):フコキサンチン及び/又はその代謝物とを含む内服用組成物。
[2]成分(a)の含有量に対する成分(b)の含有量の比率が、0.0001以上0.3未満である請求項1に記載の内服用組成物。
[3]成分(a):ラクトフェリンと成分(b):フコキサンチン及び/又はその代謝物とを有効成分とする体脂肪低減剤。
[4]成分(a):ラクトフェリンと成分(b):フコキサンチン及び/又はその代謝物とを有効成分とする体重減少促進剤。
[5]成分(a):ラクトフェリンと成分(b):フコキサンチン及び/又はその代謝物とを有効成分とする血中中性脂肪低減剤。
[6]成分(a):ラクトフェリンと成分(b):フコキサンチンとを有効成分とする血中遊離脂肪酸低減剤。
実施例で用いるコンブ由来フコキサンチン(FX)を以下の手順で製造した。
分液漏斗に、フコキサンチン1%オイル(株式会社サウスプロダクト製、コンブ由来)500g、ヘキサン500g、メタノール500gおよび飽和食塩水50gを入れ、1分間混合後、10分間静置し、下層(濃赤色)を回収した。残った上層(濃緑色)に対し、メタノール250gおよび飽和食塩水25gを入れて同様の操作を行い、下層を回収した。これら回収した下層とヘキサン250gとを分液漏斗にて混合し10分間静置後、下層を回収してエバポレーターで濃縮乾固させ、固形分を得た。得られた固形分をジエチルエーテル250gに溶解して分液漏斗に入れ、水100gを混合し10分間静置した。上層(濃赤色)を集め、硫酸ナトリウムで乾燥させて濾紙で濾過後、得られる濾液をエバポレーターで濃縮乾固し、粗製フコキサンチンを得た(17g、フコキサンチン純度:28%、フコキサンチン回収率:95%)。粗製フコキサンチンを下記2の工程に供した。
粗製フコキサンチン(9g)をヘキサン/アセトン=50/50(v/v) 50mLに溶解し、シリカゲルクロマトグラフィー(φ50mm×H500mm)にて精製した。展開はヘキサン/アセトン比率=70/30で開始し、最終比率を50/50とした。濃赤色の画分を集め、エバポレーターにて濃縮乾固し、精製フコキサンチンを得た(3.5g、フコキサンチン純度:65%、フコキサンチン回収率:92%)。精製フコキサンチンを下記3の工程に供した。
精製フコキサンチン(3.5g)を最小量のアセトンに溶解させ、水を適量添加し、エバポレーターを用いて結晶が析出しない程度にアセトンを留去した。その後、溶液を氷冷して結晶が生成するまで静置した。ヘキサンを洗浄液として吸引濾過を行い、結晶を集乾燥させ、高純度フコキサンチン(2g、フコキサンチン純度:99%、フコキサンチン回収率:83%)を得た。
・試料:20mgを精秤し、エタノールで50mLまで希釈して得られた溶液を10μL導入した。
・カラム:Inertsil ODS−3 (5μm,4.6mm(I.D.)×150mm)
・移動相:メタノール/水=85/15(0分〜)、100/0(8分〜)、100/0(35分〜)
・流速:1.0mL/min
・オーブン:60℃
・検出器:UV−VIS(440nm)
回収率=各工程の結果物におけるフコキサンチン重量/各工程の処理前の試料におけるフコキサンチン重量
フコキサンチン重量は、試料の重量に、上記のとおり測定されたフコキサンチンの純度を乗じて算出した。なお、各精製工程における処理前の試料とは、それぞれフコキサンチン1%オイル、粗製フコキサンチン、精製フコキサンチンである。
肥満モデル動物であるKK−Ayマウス(オス、5週齢)を用いて、体重、体脂肪低減、および中性脂肪および遊離脂肪酸の低減の評価を行った。
実施例で用いた餌の代わりに、通常食に質量比1質量%のラクトフェリンを添加した餌を用いたほかは、実施例1と同様に評価を行った(LF1%群、N=7)。
実施例で用いた餌の代わりに、通常食に質量比5質量%のラクトフェリンを添加した餌を用いたほかは、実施例1と同様に評価を行った(LF5%群、N=7)。
実施例で用いた餌の代わりに、通常食に質量比0.1質量%のフコキサンチンを添加した餌を用いたほかは、実施例1と同様に評価を行った(FX0.1%群、N=7)。
実施例で用いた餌の代わりに、通常食に質量比0.001質量%のフコキサンチンを添加した餌を用いたほかは、実施例1と同様に評価を行った(FX0.1%群、N=7)。
実施例で用いた餌の代わりに、通常食に質量比0.1質量%のショウガエキス(日本粉末薬品株式会社)を添加した餌を用いたほかは、実施例1と同様に評価を行った(GIN0.1%群、N=7)。
実施例で用いた餌の代わりに、通常食に質量比1質量%のラクトフェリンおよび質量比0.1質量%のショウガエキス(日本粉末薬品株式会社)を添加した餌を用いたほかは、実施例1と同様に評価を行った(LF1%+GIN0.1%群、N=7)。
ラクトフェリン100mg、フコキサンチン0.3mg、乳糖110mg、結晶セルロース80mg、カルボキシメチルセルロース−Ca5mg、及びショ糖脂肪酸エステル5mgを定法どおり打錠し、タブレットを作成した。
ラクトフェリン300mg、フコキサンチン1mg、デキストリン699mgを定法どおり造粒し、顆粒を作成した。
Claims (12)
- 成分(a):ラクトフェリンと成分(b):フコキサンチン、フコキサンチノール及びアマロシアキサンチンからなる群より選ばれる少なくとも1つとを有効成分とする体脂肪低減剤。
- 成分(a):ラクトフェリンと成分(b):フコキサンチン、フコキサンチノール及びアマロシアキサンチンからなる群より選ばれる少なくとも1つとを有効成分とする体重減少促進剤。
- 成分(a):ラクトフェリンと成分(b):フコキサンチン、フコキサンチノール及びアマロシアキサンチンからなる群より選ばれる少なくとも1つとを有効成分とする血中中性脂肪低減剤。
- 成分(a):ラクトフェリンと成分(b):フコキサンチン、フコキサンチノール及びアマロシアキサンチンからなる群より選ばれる少なくとも1つとを有効成分とする血中遊離脂肪酸低減剤。
- 成分(a)の含有量に対する成分(b)の含有量の比率が、0.0001以上0.3未満である、請求項1〜4のいずれか1項に記載の剤。
- 成分(a)の適用量が、10mg〜2000mg/日である、請求項1〜4のいずれか1項に記載の剤。
- 成分(b)の適用量が、0.01mg〜10mg/日である、請求項1〜4のいずれか1項に記載の剤。
- 成分(a):ラクトフェリンと成分(b):フコキサンチン、フコキサンチノール及びアマロシアキサンチンからなる群より選ばれる少なくとも1つを含む、体脂肪低減用、体重減少促進用、血中中性脂肪低減用、又は血中遊離脂肪酸低減用食品組成物。
- 成分(a):ラクトフェリンと成分(b):フコキサンチン、フコキサンチノール及びアマロシアキサンチンからなる群より選ばれる少なくとも1つを含む、高血圧、高血糖又は脂質異常症の予防、改善又は治療用医薬組成物。
- 成分(a)の含有量に対する成分(b)の含有量の比率が、0.0001以上0.3未満である、請求項8又は9に記載の組成物。
- 成分(a)の適用量が、10mg〜2000mg/日である、請求項8又は9に記載の組成物。
- 成分(b)の適用量が、0.01mg〜10mg/日である、請求項8又は9に記載の組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014257747A JP6399920B2 (ja) | 2014-12-19 | 2014-12-19 | 体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤 |
KR1020177015167A KR20170095843A (ko) | 2014-12-19 | 2015-12-18 | 내복용 조성물 |
CN201580069149.8A CN107106633A (zh) | 2014-12-19 | 2015-12-18 | 内服用组合物 |
PCT/JP2015/085450 WO2016098874A1 (ja) | 2014-12-19 | 2015-12-18 | 内服用組成物 |
TW104142587A TWI691334B (zh) | 2014-12-19 | 2015-12-18 | 內服用組成物、製劑、與用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014257747A JP6399920B2 (ja) | 2014-12-19 | 2014-12-19 | 体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016117676A JP2016117676A (ja) | 2016-06-30 |
JP2016117676A5 JP2016117676A5 (ja) | 2017-08-17 |
JP6399920B2 true JP6399920B2 (ja) | 2018-10-03 |
Family
ID=56126754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014257747A Active JP6399920B2 (ja) | 2014-12-19 | 2014-12-19 | 体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6399920B2 (ja) |
KR (1) | KR20170095843A (ja) |
CN (1) | CN107106633A (ja) |
TW (1) | TWI691334B (ja) |
WO (1) | WO2016098874A1 (ja) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006083102A (ja) * | 2004-09-16 | 2006-03-30 | Four Leaf Japan:Kk | 抗酸化組成物およびこれを含む製品 |
JP5012505B2 (ja) * | 2005-05-24 | 2012-08-29 | 株式会社カネカ | 抗肥満活性剤及び肥満抑制方法 |
JP5158307B2 (ja) * | 2006-09-15 | 2013-03-06 | ライオン株式会社 | 脂肪減少促進剤及び代謝異常症候群改善薬 |
CN101721403A (zh) * | 2008-10-16 | 2010-06-09 | 北京绿色金可生物技术股份有限公司 | 岩藻黄素在减肥方面的应用 |
JP2011001333A (ja) * | 2009-06-22 | 2011-01-06 | Lion Corp | アシル−CoA合成阻害剤 |
JP5815566B2 (ja) * | 2011-01-21 | 2015-11-17 | ライオン株式会社 | 脂肪分解促進用組成物 |
JP2013060402A (ja) * | 2011-09-14 | 2013-04-04 | Furabamin:Kk | フコキサンチンおよびフコイダン含有組成物 |
US20150216779A1 (en) * | 2012-08-14 | 2015-08-06 | The Texas A&M University System | Compositions for targeted anti-aging therapy |
CN103012327B (zh) * | 2012-12-21 | 2015-05-13 | 国家海洋局第三海洋研究所 | 岩藻黄质的制备方法 |
JP6208604B2 (ja) * | 2014-03-14 | 2017-10-04 | ライオン株式会社 | 体脂肪低減剤 |
-
2014
- 2014-12-19 JP JP2014257747A patent/JP6399920B2/ja active Active
-
2015
- 2015-12-18 CN CN201580069149.8A patent/CN107106633A/zh active Pending
- 2015-12-18 TW TW104142587A patent/TWI691334B/zh active
- 2015-12-18 WO PCT/JP2015/085450 patent/WO2016098874A1/ja active Application Filing
- 2015-12-18 KR KR1020177015167A patent/KR20170095843A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
TW201625293A (zh) | 2016-07-16 |
WO2016098874A1 (ja) | 2016-06-23 |
CN107106633A (zh) | 2017-08-29 |
JP2016117676A (ja) | 2016-06-30 |
TWI691334B (zh) | 2020-04-21 |
KR20170095843A (ko) | 2017-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5189365B2 (ja) | 体内脂質改善組成物 | |
JP6016363B2 (ja) | 脳神経細胞新生剤 | |
JP2005068060A (ja) | ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法 | |
WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
KR20080108523A (ko) | 지방 축적 억제제 | |
TWI610680B (zh) | 含有去鼠李糖洋丁香酚苷(Des Rhamnosyl Acteoside)之橄欖萃取物 | |
JP5158307B2 (ja) | 脂肪減少促進剤及び代謝異常症候群改善薬 | |
JP6293099B2 (ja) | ジンセノサイドf2の肝疾患予防又は治療用途 | |
JP2013071909A (ja) | 脳内過酸化脂質蓄積抑制剤 | |
EP2908828B1 (en) | Galactagogue compositions based on phosphatidylserine | |
JP6460402B2 (ja) | コレステロール排出促進用医薬組成物又は食品組成物 | |
JP6399920B2 (ja) | 体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤 | |
WO2021152400A1 (en) | Compositions comprising pig stomach mucins and uses thereof | |
JP5546833B2 (ja) | アセトアルデヒド・エタノール低減剤 | |
JP2012131760A (ja) | 脂肪酸吸収抑制剤 | |
TWI442920B (zh) | 香椿萃取物於減少體重或以降低體脂肪之藥物上之用途 | |
JP5122924B2 (ja) | 抗肥満剤 | |
JP2016172693A (ja) | 米タンパク質を有効成分とする血清尿酸低下剤 | |
WO2022085603A1 (ja) | 筋量増加、筋力増加、筋量減少抑制又は筋力低下抑制用組成物 | |
JP2018008912A (ja) | 臓器線維化抑制組成物 | |
JP7137368B2 (ja) | ナトリウム排泄促進用及び/又はナトリウム吸収抑制用組成物 | |
JP5706142B2 (ja) | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、tg低下剤、糞中脂肪排泄促進剤 | |
JP2004002254A (ja) | 植物抽出エキスを含有する腸溶性の脂肪吸収抑制剤およびそれを含有する食品 | |
JP2022118264A (ja) | 脂質排泄促進剤 | |
JP2023054194A (ja) | 防風通聖散エキス |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170704 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180425 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180814 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180904 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6399920 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |